VNRX•prnewswire•
VolitionRx Secures $2.0 Million in Funding
Summary
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 8, 2026 by prnewswire